Last-ditch plea for "reverse payment" deals ban in US health reform bill
This article was originally published in Scrip
Executive Summary
The US Federal Trade Commission's chairman Jon Leibowitz, along with key Democratic lawmakers from the House of Representatives, have stepped up their call for inclusion of a provision in the healthcare reform legislation that would ban so-called "reverse payment" or "pay-for-delay" deals – the arrangements surrounding patent litigation whereby brand companies allegedly pay off generic competitors in exchange for a delayed generic launch.